0A43 Stock Chart & Stats
$1.30
$0.03(2.91%)
At close: 4:00 PM EDT
$1.30
$0.03(2.91%)
Day’s Range― - ―
52-Week Range$0.57 - $2.97
Previous CloseN/A
Volume34.22K
Average Volume (3M)152.57K
Market Cap
$147.86M
Enterprise Value$61.11
Total Cash (Recent Filing)$36.67M
Total Debt (Recent Filing)$8.00M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Nov 10, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding103,397,514
10 Day Avg. Volume53,090
30 Day Avg. Volume152,570
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.39
Price to Sales (P/S)1248.52
P/FCF Ratio-0.92
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.17Price Target Upside143.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.88
Revenue Forecast (FY)$666.67K
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressAdvancing regulatory review and completed prelicensure inspections move INO-3.11k closer to a potential commercial decision. While approval is not assured, this progress can reduce development uncertainty, support launch planning, and create a clearer path to future product revenue.
Platform ValidationPositive partner Phase III results provide clinical validation for Inovio’s DNA medicine platform beyond its own programs. External success may strengthen scientific credibility, support future partnering interest, and improve the long-term prospects of additional pipeline candidates.
Cost Control And RunwayLower operating expenses demonstrate active cost discipline, while new capital extends funding for ongoing development and prelaunch activities. This combination gives management additional time to pursue the regulatory milestone and prepare commercialization without an immediate funding gap.
Bears Say
No Commercial RevenueThe absence of meaningful product revenue leaves Inovio dependent on collaborations, financing, and future regulatory success rather than self-funded operations. Persistent losses also indicate that the business has not yet demonstrated a sustainable commercial model or path to breakeven.
Cash Burn And LiquidityHeavy ongoing cash consumption and a limited projected runway constrain strategic flexibility over the next several quarters. Inovio may need additional financing before achieving product revenue, creating funding dependence and potential dilution while increasing execution pressure.
Regulatory UncertaintyUnresolved accelerated-approval eligibility and confirmatory-trial requirements could delay commercialization or increase development obligations. These decisions directly affect the timing, cost, and probability of converting INO-3.11k’s clinical progress into durable revenue.
Inovio Pharmaceuticals News
0A43 FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest share price was $0.57 and its highest was $2.97 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $147.86M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 63 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.217 by $0.147.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.2.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 103,397,514 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.217. Following the earnings report the stock price went up 18.301%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0A43
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.17 (143.59% Upside)
$3.17 (143.59% Upside)
Blogger Sentiment
Bullish
GB:0A43 Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
0A43 Company Deck
0A43 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful progress on the regulatory front (target PDUFA date, completed inspections, an FDA informal meeting) and tangible commercial/pipeline milestones (partner Phase III success, DPROT preclinical progress, Syneos engagement). Financially the company cut costs and completed an $18.3M equity offering that extends runway into late Q1 2027. However, material risks remain: near‑term liquidity is tight with an $18M projected Q3 burn, net loss improvement was substantially driven by a noncash warrant gain, regulatory uncertainties persist around accelerated approval eligibility and confirmatory trial design feedback, and competitive uptake of a rival product exists. Taken together, positives around regulatory momentum and platform validation are balanced by financing, regulatory, and execution risks.View all GB:0A43 earnings summaries0A43 Stock 12 Month Forecast
Average Price Target
$3.17
▲(143.59% Upside)
Technical Analysis
Agenus
―
Oncolytics Biotech
―
―
Atossa Therapeutics
―
Anixa Biosciences
―
Instil Bio
―